CALT - Wutah pendapatan YoY sajrone 12 wulan kepungkur Calliditas Therapeutics

Calliditas Therapeutics (CALT) minimizes risks by focusing on therapies for rare nephrological pathologies with high demand. The GURU.Markets platform reflects the year-over-year sales trajectory (TTM), where the 178.60 indicator determines the metric's magnitude. Calliditas Therapeutics is striving for the expansion of the drug Tarpeyo to capture market share, while support from a European behemoth and a 100% patient retention rate strengthen its regulatory status.
calliditas.se (CALT) - rincian metrik lan laporan keuangan

This indicator measures the rolling revenue growth rate over the last 12 months, allowing for the capture of real-time market shifts prior to the publication of official reports. By analyzing year-over-year sales growth (TTM), an investor assesses the effectiveness of Calliditas Therapeutics (CALT) expansion into new markets and the successful implementation of rare kidney disease therapies supported by insurance companies.